Akademik Veri Yönetim Sistemi
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025 (SCI-Expanded, Scopus)
Purpose RAS mutations play a critical role in the pathogenesis and progression of colorectal cancer. This study aimed to
evaluate the clinical and pathological characteristics associated with RAS mutation status and to investigate its prognostic
value in patients with metastatic colorectal cancer.
Methods This retrospective study included 446 adult patients with metastatic colorectal cancer followed at Dokuz Eylul
University Medical Oncology Department between 2010 and 2016, all of whom had available RAS mutation data and complete
clinical records.
Results RAS mutations were identified in 44.8% of patients, predominantly KRAS codon 12 mutations. Early-stage disease
and absence of metastasis at diagnosis were more common in the RAS wild-type (WT) group (p < 0.001). Lung metastases
occurred more frequently in RAS-mutant cases (p = 0.006). No significant difference in overall survival (OS) was observed
between RAS-mutant and WT groups (53.6 vs. 52.5 months; p > 0.05). Anti-VEGF therapy conferred a modest OS benefit
in RAS-mutant patients, whereas anti-EGFR therapy showed no effect. Among KRAS-mutant subtypes, codon 61 mutations
were associated with the poorest OS.
Conclusion RAS mutation status may provide insight into metastatic patterns and disease stage in patients with metastatic
colorectal cancer. However, its impact on overall survival remains inconclusive. Further prospective studies are needed to
clarify its prognostic value.